Literature DB >> 26583350

Screening for cognitive dysfunction in unipolar depression: Validation and evaluation of objective and subjective tools.

Caroline Vintergaard Ott1, Anne Juul Bjertrup2, Johan Høy Jensen3, Henrik Ullum4, René Sjælland5, Scot E Purdon6, Eduard Vieta7, Lars V Kessing8, Kamilla W Miskowiak9.   

Abstract

BACKGROUND: Persistent cognitive dysfunction in unipolar depression (UD) contributes to socio-occupational impairment, but there are no feasible methods to screen for and monitor cognitive dysfunction in this patient group. The present study investigated the validity of two new instruments to screen for cognitive dysfunction in UD, and their associations with socio-occupational capacity.
METHOD: Participants (n=53) with UD in partial or full remission and healthy control persons (n=103) were assessed with two new screening instruments, the Danish translations of the Screen for Cognitive Impairment in Psychiatry (SCIP-D) and Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA) and with established neuropsychological and self-assessment measures. Depression symptoms and socio-occupational function were rated with the Hamilton Depression Rating Scale and Functional Assessment Short Test respectively.
RESULTS: The SCIP-D and COBRA were valid for detection of objective and subjective cognitive impairment, respectively. The three parallel SCIP-D forms were equivalent. A combined SCIP-D-COBRA measure showed high sensitivity and good specificity for objective cognitive impairment (91% and 70%, respectively). There was no correlation between subjective and objective measures of cognition. Subjective cognitive difficulties correlated more with socio-occupational impairment (r=0.7, p<0.01) than did objective cognitive difficulties, for which there was a weak correlation with the executive skills domain only (r =-0.3, p=0.05). LIMITATIONS: A modest sample size.
CONCLUSIONS: The SCIP-D and COBRA are valid measures of objective and subjective cognitive impairment, respectively, and should ideally be implemented together in the screening for cognitive dysfunction in UD.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Assessment; Cognition; Depression; Mood disorder; Screening; Socio-occupational function

Mesh:

Year:  2015        PMID: 26583350     DOI: 10.1016/j.jad.2015.10.059

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  23 in total

1.  Using the cognitive assessment interview to screen cognitive impairment in psychosis.

Authors:  Ana M Sánchez-Torres; María Rosa Elosúa; Ruth Lorente-Omeñaca; Lucía Moreno-Izco; Victor Peralta; Joseph Ventura; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-06-06       Impact factor: 5.270

2.  Impact of pretreatment interhemispheric hippocampal asymmetry on improvement in verbal learning following erythropoietin treatment in mood disorders: a randomized controlled trial

Authors:  Kamilla W. Miskowiak; Julie L. Forman; Maj Vinberg; Hartwig R. Siebner; Lars V. Kessing; Julian Macoveanu
Journal:  J Psychiatry Neurosci       Date:  2020-05-01       Impact factor: 6.186

3.  Does Subjective Cognitive Function Mediate the Effect of Affective Temperaments on Functional Disability in Japanese Adults?

Authors:  Kuniyoshi Toyoshima; Takeshi Inoue; Jiro Masuya; Yota Fujimura; Shinji Higashi; Ichiro Kusumi
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-08       Impact factor: 2.570

4.  Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G).

Authors:  Gabriele Sachs; Iris Lasser; Scot E Purdon; Andreas Erfurth
Journal:  Schizophr Res Cogn       Date:  2021-05-12

5.  Discrepancy between objective and subjective cognition in adults with major depressive disorder.

Authors:  Manit Srisurapanont; Sirijit Suttajit; Kanokkwan Eurviriyanukul; Prirada Varnado
Journal:  Sci Rep       Date:  2017-06-20       Impact factor: 4.379

6.  Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.

Authors:  Jeff Zarp Petersen; Lejla Sjanic Schmidt; Maj Vinberg; Martin Balslev Jørgensen; Ida Hageman; Hannelore Ehrenreich; Gitte Moos Knudsen; Lars Vedel Kessing; Kamilla Woznica Miskowiak
Journal:  Trials       Date:  2018-11-06       Impact factor: 2.279

7.  An ethnographic study of the effects of cognitive symptoms in patients with major depressive disorder: the IMPACT study.

Authors:  Bjarke Ebert; Kamilla Miskowiak; Morten Kloster; Jon Johansen; Cara Eckholm; Torbjörn Wærner; Mads Holme; Louise Meldgaard Bruun
Journal:  BMC Psychiatry       Date:  2017-11-21       Impact factor: 3.630

8.  Amyloid Plaques and Symptoms of Depression Links to Medical Help-Seeking due to Subjective Cognitive Decline.

Authors:  Ragna Espenes; Bjørn-Eivind Kirsebom; Cecilia Eriksson; Knut Waterloo; Erik Hessen; Stein Harald Johnsen; Per Selnes; Tormod Fladby
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

9.  Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial.

Authors:  Kerstin K Antonsen; Mette K Klausen; Amanda S Brunchmann; Nina le Dous; Mathias E Jensen; Kamilla Woznica Miskowiak; Patrick M Fisher; Gerda K Thomsen; Henrik Rindom; Thomas P Fahmy; Sabine Vollstaedt-Klein; Helene Benveniste; Nora D Volkow; Ulrik Becker; Claus Ekstrøm; Gitte Moos Knudsen; Tina Vilsbøll; Anders Fink-Jensen
Journal:  BMJ Open       Date:  2018-07-16       Impact factor: 2.692

Review 10.  Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review.

Authors:  Andrea Fiorillo; Bernardo Carpiniello; Serafino De Giorgi; Silvestro La Pia; Giuseppe Maina; Gaia Sampogna; Edoardo Spina; Alfonso Tortorella; Antonio Vita
Journal:  Front Psychiatry       Date:  2018-10-11       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.